PTCT vs SRRK
PTCT: A commercial-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for rare genetic diseases. SRRK: Scholar Rock is a clinical-stage biopharma company pioneering anti-myostatin therapies to treat rare neuromuscular diseases like SMA by selectively inhibiting growth factor activation.
Side-by-side fundamentals
| Metric | PTCT | SRRK | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $71.06 | $58.20 | |
| Market cap as of 2026-08-24 | $5.9B | $7.1B | |
| PEG as of 2026-08-24 | 0.86 | -1.11 | SRRK lower |
| Net margin as of 2026-08-24 | -3.8% | -237.0% | PTCT higher |
| Gross margin as of 2026-08-24 | +93.0% | n/a | |
| Operating margin as of 2026-08-24 | +12.4% | -231.8% | PTCT higher |
| ROE as of 2026-08-24 | -351.9% | -159.1% | SRRK higher |
| ROA as of 2026-08-24 | -1.3% | -86.6% | PTCT higher |
| Debt / equity as of 2026-08-24 | 848.93 | 0.77 | SRRK lower |
| Revenue growth (YoY) as of 2026-08-24 | -42.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +35.3% | n/a | |
| Beta as of 2026-08-24 | 0.96 | 1.30 | |
| 1-year return as of 2026-08-24 close | +40.5% | +64.0% | SRRK higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.